The health ministry may soon ban over 300 fixed-dose combination (FDCNSE -1.99 %) medicines, accepting recommendations of a sub-committee of India’s apex drug advisory body. The move, which is expected to impact top MNCs such as AbbottNSE 1.87 % as well as domestic players such as PiramalNSE -1.98 %, Macleods, Cipla and Lupin among others, could be challenged in the courts once again.

If the initial draft ban notification that ET has viewed are implemented, the ban would cover popular cough syrups, pain killers and flu medicines like Phensedyl, Saridon and D’Cold Total. The draft lists out 343 FDCs that the ministry plans to ban manufacture, sale and distribution of and has been prepared based on recommendations of the Drug Technical Advisory Board (DTAB).

The Supreme Court had last year asked the DTAB to recommend to the health ministry which FDCs should be regulated or restricted or banned outright along with reasons for doing so. This followed an extended legal battle between the government and drug companies over the FDC ban issue.

The final notification is expected in the coming week, said officials in the know. “The health ministry will duly ban 343 FDCs,” confirmed one official. Read More